What is HydroCision?
HydroCision, Inc. operates at the intersection of surgical precision and medical innovation. The company has developed a proprietary FluidJet platform that utilizes high-velocity fluid streams to perform delicate tissue resection without the heat-related complications associated with traditional electrosurgical tools. This unique patent estate has allowed the firm to establish a robust footprint across diverse clinical verticals, including wound care, urology, spine surgery, and orthopedic sports medicine. By focusing on minimally invasive techniques, HydroCision addresses critical gaps in surgical outcomes, positioning itself as a vital player in the evolving landscape of modern healthcare technology.
How much funding has HydroCision raised?
HydroCision has raised a total of $36.5M across 10 funding rounds:
Series F
$5.2M
Series G
$12.7M
Debt
$3M
Debt
$623K
Private Equity
$3M
Other Financing Round
$4M
Debt
$150K
Debt
$279K
Series F (2002): $5.2M, investors not publicly disclosed
Series G (2006): $12.7M, investors not publicly disclosed
Debt (2008): $3M, investors not publicly disclosed
Debt (2010): $623K, investors not publicly disclosed
Private Equity (2017): $3M led by Volcano Capital, LLC and BioVentures Investors, LLC
Other Financing Round (2017): $4M supported by Tradewind International
Debt (2020): $150K featuring PPP
Debt (2021): $279K backed by PPP
Key Investors in HydroCision
Volcano Capital, LLC
An evergreen fund focused exclusively on the healthcare sector, providing operational and strategic expertise to early-to-mid-stage medical device companies.
BioVentures Investors, LLC
A specialized MedTech investment firm dedicated to supporting innovative companies that aim to improve global healthcare outcomes through advanced technology.
Oxford Bioscience Partners
An international venture capital firm with a deep focus on life science technology investments, maintaining a global presence in key innovation hubs.
What's next for HydroCision?
Looking ahead, HydroCision is well-positioned to leverage its established intellectual property to scale its commercial operations. The company's trajectory, marked by a blend of equity financing and strategic debt, suggests a focus on long-term value creation rather than rapid, unsustainable expansion. Future growth will likely center on deepening market penetration within its core surgical segments and potentially exploring new clinical applications for its FluidJet technology. As the firm moves beyond its current development phase, the emphasis will remain on maintaining its competitive advantage through rigorous clinical validation and strategic partnerships that enhance its global distribution capabilities.
See full HydroCision company page
